24/7 Market News- IMUNON Reports Positive Phase 2 OVATION 2 Study Data

July 30, 2024

DENVER, Colo., Jul 30, 2024 (247marketnews.com)- IMUNON, Inc. (NASDAQ:IMNN) reported positive topline results from the Phase 2 OVATION 2 study with IMNN-001 in patients with advanced ovarian cancer.

Highlights from the randomized study of patients treated with IMNN-001 plus standard-of-care in a first-line treatment setting included an 11.1 month increase in median OS compared with standard-of-care alone in the intent-to-treat population (ITT) and a hazard ratio in the ITT population of 0.74, which indicates a 35% improvement in survival.

IMUNON’s President and CEO, Stacy Lindborg, commented, “These strong and clinically meaningful Phase 2 results are highly encouraging, suggesting that IMNN-001 may improve the outcomes for women with advanced ovarian cancer. In the near term, we look forward to advancing our therapeutic into a Phase 3 pivotal study as soon as possible.

“Advancements in treatment options for advanced ovarian cancer in women who require neoadjuvant treatment have been limited over the years, and these patients continue to have poor prognoses. Our goal is for IMNN-001 to play an important role in the treatment regimen for the more than 300,000 women diagnosed with this deadly disease. On behalf of IMUNON, I extend heartfelt thanks to the women who participated in this trial, their families and the investigators.”

IMUNON’s Chief Medical Officer, Sebastien Hazard, M.D., stated, “It is highly gratifying to witness the extraordinary overall survival benefit that IMNN-001 showed in this Phase 2 study further supported by consistency across data, including in progression-free survival and in the patients who received three doses or more of IMNN-001 gaining an additional 15.7 months of life, while the safety profile was tolerable. It suggests that IMUNON’s IL-12 gene therapy has a long-term impact on the disease.”

IMUNON believes that the Phase 3 study will begin in the first quarter of 2025.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (IMNN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.